Impel Pharmaceuticals Revenue, Growth & Competitor Profile

DBA IMPEL BIOPHARMACEUTICALS
DBA IMPEL NEUROPHARMA INC

Company Profile & Annual Report for Impel Pharmaceuticals

Access the complete profile.

Impel Pharmaceuticals Fast Facts

Revenue	$100 - $500 million    See Exact Annual Revenue
Employees	100 - 500Exact Company Size
Primary Industry	325411 Medicinal & Botanical Manufacturing
Additional NAICS Codes	325412 Pharmaceutical Preparation Manufacturing 5417 Scientific Research & Development Services
Address	201 Elliott Ave W Ste 260 Seattle, WA 98119

Note: Revenues for privately held companies are statistical evaluations.


Impel Pharmaceuticals's Annual Report & Profile shows critical firmographic facts:

• What is the company's size? (Annual sales and employees)
  • Impel Pharmaceuticals's annual revenues are $100 - $500 million (see exact revenue data)
• What industry is the company in?
  • Impel Pharmaceuticals is classified as operating in the Medicinal & Botanical Manufacturing industry, NAICS Code 325411.

Impel Pharmaceuticals Annual Revenue and Growth Rate

Impel Pharmaceuticals	Revenue Est. ($ Million)	Growth Rate (%)	# Employees
2025	$100 - $500 million Details in Premium Report
2024
2023
2021
2020
2019

1-Year Growth Rate: 3-Year Growth Rate (CAGR):

Note: Impel Pharmaceuticals's revenues are gauged from an analysis of company filings.

Impel Pharmaceuticals's Income Statement (based on Industry Averages)

Impel Pharmaceuticals P&L	$ Millions
Revenue (Sales)
Cost of Goods Sold
Gross Profit
Operating Expenses
Advertising
Salaries and wages
Other Operating Expenses
Total Operating Expenses
Operating Income
EBITDA
EBIT (Earnings Before Interest and Taxes)
Net Profit

Trademark Applications

Trademark applications show the products and services that Impel Pharmaceuticals is developing and marketing. Impel Pharmaceuticals doesn't have any recent trademark applications, indicating Impel Pharmaceuticals is focusing on its existing business rather than expanding into new products and markets. Trademarks may include brand names, product names, logos and slogans.

Trademark	Date
TRUDHESA Pharmaceutical preparations for the treatment and alleviation of migraine headaches	08/14/2019
TULIFTA Pharmaceutical preparations for the treatment and alleviation of migraine headaches	08/14/2019

See all trademarks and details in the Full Report.

Market Share of Impel Pharmaceuticals's Largest Competitors

A competitive analysis shows these companies are in the same general field as Impel Pharmaceuticals, even though they may not compete head-to-head. These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines. The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies. Competitive advantage comes from offering better pricing or superior products/service.

Company	Headquarters	Revenue ($ MM)
XYMOGEN	Orlando, FL	100
AVANTI NUTRITIONAL LABORATORIES	Miami Lakes, FL	37
NUTRITION FORMULATORS	Miramar, FL	36
RTPR	Cabot, AR	33
INTEGRATED BOTANICS	Fort Worth, TX	29
COSMAX NBT USA	Garland, TX	29
CJB INDUSTRIES	Valdosta, GA	28
ALTERNATIVE LABORATORIES	Naples, FL	28
S&B PHARMA	Azusa, CA	28

Nearby Competitors

These companies are similar in business line and location to Impel Pharmaceuticals. While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.

Company	Headquarters	Revenue ($ MM)
JUST-EVOTEC BIOLOGICS	Seattle, WA	100
IMPEL PHARMACEUTICALS	Seattle, WA	61
TILRAY	Seattle, WA	48
UMOJA BIOPHARMA	Seattle, WA	32
ZYMEWORKS BIOPHARMACEUTICALS	Seattle, WA	21
APTEVO THERAPEUTIC	Seattle, WA	11

Future Competition: Impel Pharmaceuticals's Fastest Growing Competitors

These companies are in the same general field as Impel Pharmaceuticals and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.

Company	Revenue ($ MM)